To resolve whether CaMKK2 in stromal cells or the tumor itself might drive tumor progression, we sought to determine if CaMKK2 deficiency in the tumor-bearing host was sufficient to extend survival in syngeneic orthotopically implanted glioma models. This evidence concerns the gene CAMKK2 and central nervous system cancer.